Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
DC CAFCFirst Claim
1. A method of treating Parkinson'"'"'s Disease psychosis in a patient, comprising administrating to a patient having Parkinson'"'"'s Disease a therapeutically effective amount of N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof.
3 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson'"'"'s Disease, related human neurodegenerative diseases, and psychosis.
82 Citations
11 Claims
-
1. A method of treating Parkinson'"'"'s Disease psychosis in a patient, comprising administrating to a patient having Parkinson'"'"'s Disease a therapeutically effective amount of N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (3, 4, 5, 6, 7, 8, 10)
-
2. A method of treating Parkinson'"'"'s Disease psychosis in a patient, composing administrating to a patient having Parkinson'"'"'s Disease a pharmaceutical composition comprising from about 10 mg to about 50 mg of N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (9, 11)
Specification